On July 9, Sinopharm Group (01099.HK) fell 3.38% in regular trading, trading at HK$16.6/share, with turnover of HK$84.11 million. The decline comes amid a wave of institutional selling pressure.

On the news front, JPMorgan disclosed a reduction of approximately 874,000 shares on June 30 at HK$16.0054 per share, bringing its stake to 5.97%. Earlier, BlackRock reduced its long position from 10.19% to 9.63% on June 22, while FMR LLC sold 2 million shares at HK$16.82 on June 16. Southbound funds have also been net sellers, with cumulative net reductions of approximately 14.64 million shares over the past 20 trading days. While China CITIC Financial Asset Management increased its position on June 26, overall institutional selling pressure has weighed on market confidence.

Within the Health Care Distributors sector, the broader group traded lower. Among individual stocks, 160 Health down 3.38%, Baiyunshan Pharma down 1.23%, Shanghai Pharma down 1.69%, YSB down 5.42%, and Guanze Medical down 9.26%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)